So far, the application of anti-EGFR therapy in ovarian cancer has been shown only limited efficacy; therefore further studies will be needed to investigate whether (membranous) EGFR is also predictive for benefit from EGFR targeted therapies. The gene discussed is EGFR; the disease is ovarian cancer.